Vivo Bio Tech Ltd. (VIVOBIOT) — Tipsheet

Vivo Bio Tech profit plunges 86% despite 14% revenue growth

Tipsheet Editorial — Mon, 13 Jul 2026 19:51:51 GMT

Net profit fell to ₹1.88 crore from ₹13.37 crore a year ago as employee costs and depreciation surged. The board approved the unaudited results on July 13.

What’s new

Revenue up 14% to ₹14.28 cr in June quarter.
Net profit fell 86% to ₹1.88 cr from ₹13.37 cr a year ago.
Employee costs and depreciation surged, driving profit decline.

Why it matters

The 86% profit crash shows last year's ₹13.37 cr profit was likely a one-off. With a ₹5.44 cr loss in the March quarter and auditor flagged ₹4.19 cr in overdue dues, core operations remain weak. Revenue growth is not enough to offset rising costs.

What we’re watching

Whether revenue growth sustains above the ₹14 cr run-rate.
Impact of rising employee costs and depreciation on margins.
Any update on the proposed merger with a resort company.

The full read

Vivo Bio Tech's June quarter offers two opposing headlines. Revenue up 14% to ₹14.28 crore. Profit down 86% to ₹1.88 crore. The difference: employee costs and depreciation rose faster than sales. Last year's ₹13.37 crore profit now looks like an outlier—the March quarter had a ₹5.44 crore loss and an auditor flagged ₹4.19 crore in overdue dues. Sequential improvement from that loss is real, but the earnings quality is thin. For a ₹51 crore market-cap company, cost control remains the biggest risk. That hasn't changed.

Primary source: BSE · NSE

Vivo Bio Tech profit slumps 86% even as revenue climbs 14%

Tipsheet Editorial — Mon, 13 Jul 2026 19:43:09 GMT

Employee costs and depreciation erode margins in June quarter; net profit at ₹1.88 crore.

What’s new

Consolidated revenue rose 14% to ₹14.28 cr in June 2026 quarter.
Net profit plunged 86% to ₹1.88 cr, hit by higher employee costs and depreciation.
Results follow a ₹5.44 cr loss in Q4 FY26 and a recent promoter stake sale of 99%.

Why it matters

The profit collapse, combined with the promoter's near-complete exit and auditor flags on overdue dues, paints a deteriorating operating picture. The company has yet to provide any strategic response or guidance.

What we’re watching

Whether management addresses the cost structure in the coming quarters.
Any further promoter share sales or stake changes.
How the company plans to deal with overdue dues flagged by auditors.

The full read

Vivo Bio Tech's June quarter numbers are a mixed bag that leans adverse. Revenue rose 14% to ₹14.28 crore, but net profit collapsed 86% to ₹1.88 crore — a far cry from a year ago. The culprit: employee costs and depreciation, both jumping. That this profit (barely above a loss) comes on the heels of a ₹5.44 crore Q4 loss and a promoter who just sold 99% of its stake (4.51% of voting capital) makes the picture worse. The auditor had earlier flagged ₹4.19 crore in overdue dues. The filing itself is routine, but the numbers confirm a deteriorating business with no pivot in sight.

Primary source: BSE · NSE

Vivo Bio Tech promoter sells 99% of its stake

Tipsheet Editorial — Mon, 08 Jun 2026 17:46:24 GMT

Shri Shri Resorts cut its holding to 0.30% after dumping 10 lakh shares on the open market. The sale was about 4.5% of Vivo Bio Tech's market cap.

What’s new

Promoter entity Shri Shri Resorts sold 10 lakh Vivo Bio Tech shares on June 8, slashing its stake to 0.30% from 4.81%.
The sale was executed on the BSE open market, leaving the entity with just 67,000 shares.
The transaction is valued at about ₹2.43 crore, representing roughly 4.5% of Vivo Bio Tech's ₹54 crore market cap.

Why it matters

A promoter group entity just disposed of virtually its entire holding in a single trade. For a nano-cap where liquidity is thin, a 4.5% market-cap sale is a direct hit to the stock's available float. The move comes shortly after the company announced plans to amalgamate Shri Sh Promoter selling of this scale rarely happens without a reason, and the stock is left with a major overhang.

What we’re watching

Any follow-on sales from the remaining 67,000 shares held by Shri Shri Resorts.
Vivo Bio Tech's response, especially given the pending amalgamation announcement.
How the stock's liquidity and price react to the sudden increase in free float.

The full read

Shri Shri Resorts Private Ltd sold 10,00,000 Vivo Bio Tech shares on the BSE on June 8, dumping 4.51% of the company's voting capital in one trade. The promoter entity's stake collapsed from 4.81% to 0.30%, leaving it with just 67,000 shares. The sale is valued at about ₹2.43 crore, which is roughly 4.5% of Vivo Bio Tech's ₹54 crore market cap. This is not routine housekeeping. For a nano-cap, a promoter liquidating almost its entire holding is a loud signal, especially with a pending amalgamation involving the same entity already on the table. The stock is left with a major question mark over insider conviction.

Primary source: BSE · NSE

Vivo Bio Tech posts ₹5.44 cr Q4 loss; auditor flags ₹4.19 cr in overdue dues

Tipsheet Editorial — Sat, 30 May 2026 22:46:33 GMT

A ₹6.97 cr deferred tax charge swung the quarter to a loss. The full year turned red too, and the auditor is chasing ₹4.19 cr in unpaid statutory dues.

What’s new

Q4 net loss of ₹5.44 cr after a ₹6.97 cr deferred tax charge and higher operating costs.
Full-year revenue rose to ₹52.6 cr, but the company reported a full-year net loss of ₹1.94 cr.
Auditor flagged ₹4.19 cr in overdue statutory dues, including provident fund and tax deductions.

Why it matters

The deferred tax charge is non-cash, but it landed on top of an operating picture where costs already outpaced revenue growth. Revenue climbed to ₹52.6 cr from ₹46.7 cr, yet the company still swung from a ₹7.57 cr annual profit to a loss. The overdue statutory dues are a separate, concrete compliance failure.

What we’re watching

Whether the ₹4.19 cr in overdue statutory dues are cleared next quarter.
Progress on the proposed amalgamation with Shri Shri Resorts.
Management's plan to control costs in FY27.

The full read

Vivo Bio Tech's results show revenue growth being consumed by costs and a one-time hit. The full-year top line rose to ₹52.6 crore from ₹46.7 crore. But a ₹6.97 crore deferred tax charge in Q4 alone turned a ₹1.26 crore quarterly profit into a ₹5.44 crore loss, and dragged the full year to a ₹1.94 crore net loss. The company had made ₹7.57 crore in profit the year before. The auditor's emphasis-of-matter paragraph adds a different problem: ₹4.19 crore in unpaid statutory dues, including provident fund and tax deductions. On a separate track, the board is appointing a consultant to advance its planned merger with Shri Shri Resorts. The financial and compliance issues will dominate the near-term narrative.

Primary source: BSE · NSE

Vivo Bio Tech to consider merging a resort company into itself

Tipsheet Editorial — Mon, 25 May 2026 17:39:38 GMT

The nano-cap contract research outfit will weigh a deal with Shri Shri Resorts alongside its Q4 results on May 29.

What’s new

Vivo Bio Tech's board will meet May 29 to consider merging Shri Shri Resorts Private Ltd into itself.
The same meeting will also approve audited financial results for Q4 and FY26.
The trading window is closed until May 31 ahead of the meeting.

Why it matters

A nano-cap contract research organization looking to absorb a private resort company is, at minimum, a jarring strategic pivot. The deal is at the proposal stage, so the structure and rationale are unknown, but for a ₹59 cr market cap firm, even a small private target could materially reshape its balance sheet and business description.

What we’re watching

Details on Shri Shri Resorts' financials, size, and how the deal is structured (equity, cash, or both).
Management's rationale for merging a resort business into a CRO.
Whether the Q4 results disclose any related-party transactions or commitments.

The full read

Vivo Bio Tech, a nano-cap contract research organization with a market cap of ~₹59 crore, is exploring an unusual deal. The board will meet on May 29 to weigh merging Shri Shri Resorts Private Ltd into itself. This is the first public disclosure of the proposal. For a company this small, absorbing a private resort business could materially reshape its profile, though the structure, valuation, and strategic logic remain completely undisclosed. Alongside the merger agenda, the board will also sign off on audited Q4 and FY26 results. The trading window is shut until May 31. The core question is straightforward: why does a CRO want to merge with a resort company? The answers will need to come on May 29.

Primary source: BSE · NSE